E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Relapsed/Refractory Follicular Lymphoma |
Linfoma folicular recidivante/refractario |
|
E.1.1.1 | Medical condition in easily understood language |
Relapsed/Refractory Follicular Lymphoma |
Linfoma folicular recidivante/refractario |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 24.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10085128 |
E.1.2 | Term | Follicular lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The purpose of this randomized Phase 3 study is to evaluate the efficacy, safety, and tolerability of epcoritamab 48 mg in combination with R2 compared to R2 alone in subjects with R/R FL. |
El objetivo de este estudio aleatorizado de fase 3 es evaluar la eficacia, la seguridad y la tolerabilidad de 48 mg de epcoritamab en combinación con R2 en comparación con R2 solo en sujetos con LF R/R. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives are as follows: • To evaluate whether epcoritamab 48 mg in combination with R2 compared to R2 alone can improve clinical outcomes as measured by key secondary endpoints (including CR, best overall response [BOR], overall survival [OS], and minimal residual disease [MRD] negativity) in subjects with R/R FL. • To evaluate whether epcoritamab 24 mg in combination with R2 compared to R2 alone can improve PFS in subjects with relapsed/refractory (R/R) FL. • To evaluate whether epcoritamab 24 mg in combination with R2 compared to R2 alone can improve clinical outcomes as measured by key secondary endpoints (including CR, BOR, OS, and MRD negativity) in subjects with R/R FL. |
Evaluar si epcoritamab 48 mg en combinación con R2, en comparación con R2 solo, puede mejorar los resultados clínicos medidos por criterios de valoración secundarios clave (incluida la RC, la mejor respuesta global [MRG], la supervivencia global [SG] y la negatividad de la enfermedad mínima residual [ERM]) en sujetos con FL R/R. - Evaluar si epcoritamab 24 mg en combinación con R2, en comparación con R2 solo, puede mejorar la SSP (supervivencia sin progresión) en sujetos con FL recidivante/refractario (R/R). - Evaluar si epcoritamab 24 mg en combinación con R2 en comparación con R2 solo puede mejorar los resultados clínicos medidos por criterios de valoración secundarios clave (incluyendo RC, MRG, SG y negatividad de ERM) en sujetos con FL R/R. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Subject must be at least 18 years old. 2. Subject must have an Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2. 3. Subject has: • Fluorodeoxyglucose-positron emission tomography (FDG PET) scan demonstrating positive lesion compatible with computed tomography (CT) or magnetic resonance image (MRI)-defined anatomical tumor sites AND • ≥ 1 measurable nodal lesion (long axis ≥ 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extra-nodal lesion (long axis ≥ 1.0 cm) on CT scan or magnetic resonance image (MRI) 4. Subject must have histologically confirmed Grade 1 to 3a FL according to the World Health Organization (WHO) 2016 classification with no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy and CD20+ on a representative tumor biopsy based on the pathology report. 5. Subject must have R/R disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody in combination with (an)other anti-lymphoma agent(s). (Subject who received only prior anti-CD20 monoclonal antibody monotherapy is not eligible.) 6. Subject must be eligible to receive R2 per investigator determination |
1. El sujeto debe tener al menos 18 años. 2. El sujeto debe tener una puntuación del estado funcional del ECOG (Eastern Cooperative Oncology Group) de 0 a 2. 3. El sujeto debe presentar: - Tomografía por emisión de positrones con fluorodesoxiglucosa (PET FDG) que muestra una lesión positiva compatible con localizaciones tumorales anatómicas definidas por tomografía computarizada (TC) o resonancia magnética (RM) Y - Al menos una lesión ganglionar mensurable (eje mayor ≥1,5 cm y eje menor >1,0 cm) o al menos una lesión extra ganglionar mensurable (eje mayor ≥1,0 cm) en la TC o la RM. 4. El sujeto debe tener un LF de grado 1 a 3a confirmado histológicamente según la clasificación de 2016 de la Organización Mundial de la Salud sin indicios de transformación histológica a un linfoma agresivo en la biopsia tumoral representativa más reciente y CD20+ en una biopsia tumoral representativa basándose en el informe anatomopatológico. 5. El sujeto debe presentar enfermedad R/R con al menos una pauta sistémica previa que incluyera un anticuerpo monoclonal (AcM) anti-CD20 en combinación con otros fármacos contra el linfoma. No podrán participar los sujetos que hayan recibido únicamente un AcM anti-CD20 en monoterapia. 6. El sujeto debe ser apto para recibir R2 según la determinación del investigador. |
|
E.4 | Principal exclusion criteria |
1. Subject must not have documented refractoriness to lenalidomide, with refractoriness defined as: o Best response to lenalidomide of stable disease or progressive disease, or o Progressive disease within 6 months of completion of lenalidomide therapy 2. Subjects must not have had lenalidomide exposure within 12 months prior to randomization |
1. El sujeto no debe presentar resistencia documentada a la lenalidomida, definida como: - Mejor respuesta a la lenalidomida de enfermedad estable o progresión de la enfermedad. - Progresión de la enfermedad en los 6 meses siguientes a la finalización del tratamiento con lenalidomida. 2. Los sujetos no podrán haber tenido exposición a la lenalidomida en los 12 meses previos a la aleatorización |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Progression-Free Survival (PFS): duration from the date of randomization to the date of disease progression determined by Lugano criteria per Independent Review Committee (IRC), or death, whichever occurs first. |
Supervivencia sin progresión (SSP): tiempo transcurrido entre la fecha de la aleatorización y la fecha de la progresión de la enfermedad, determinada por los criterios de Lugano según la evaluación del comité de revisión independiente (CRI), o la muerte, lo que ocurra antes. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Throughout the study. Survival follow-up will continue until death, withdrawal of the subject, lost to follow up, study discontinuation, or study termination by the Sponsor, whichever comes first |
A lo largo del estudio. El seguimiento de la supervivencia continuará hasta la muerte, la retirada del sujeto, la pérdida de seguimiento, la interrupción del estudio o la terminación del estudio por parte del patrocinador, lo que ocurra primero |
|
E.5.2 | Secondary end point(s) |
•Complete Response (CR) during the study, determined by Lugano criteria, as assessed by IRC •Best overall response (BOR) of CR or partial response (PR), determined by Lugano criteria, as assessed by IRC •Overall survival (OS) •Minimal residual disease (MRD) negativity |
• Respuesta completa (RC) durante el estudio, determinada mediante los criterios de Lugano, según la evaluación del CRI. • Mejor respuesta global (MRG) de RC o respuesta parcial (RP), determinada mediante los criterios de Lugano, según la evaluación del CRI. • Supervivencia global (SG). • Negatividad de la enfermedad residual mínima (ERM) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
-CR/BOR: Throughout the study. -MRD: Throughout study till Post-Treatment Follow-up visits which will occur for a period of 5 years after the last subject has been randomized or until discontinuation, whichever comes first. -Survival: Throughout the study until death, withdrawal of the subject, lost to follow up, study discontinuation, or study termination by the Sponsor, whichever comes first |
-CR/MRG: Durante todo el estudio. -CR/ERM: Durante todo el estudio hasta las visitas de seguimiento posteriores al tratamiento, que tendrán lugar durante un período de 5 años después de que el último sujeto haya sido aleatorizado o hasta la interrupción, lo que ocurra primero. -Supervivencia: Durante todo el estudio hasta la muerte, la retirada del sujeto, la pérdida de seguimiento, la interrupción del estudio o la finalización del estudio por parte del promotor, lo que ocurra primero. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 15 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 120 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Australia |
Brazil |
Canada |
China |
Israel |
Japan |
Korea, Republic of |
New Zealand |
Puerto Rico |
South Africa |
Taiwan |
United States |
Austria |
France |
Poland |
Sweden |
Netherlands |
Spain |
Switzerland |
Czechia |
Germany |
Greece |
Italy |
Belgium |
Denmark |
Hungary |
Slovakia |
Turkey |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The global end of this study shall be defined as the point at which all enrolled subjects have completed all study-specified follow-up (last subject, last visit in the last country where the study was conducted) or the last subject dies or withdraws from the study in the last country where the study was conducted. However, the maximum trial duration is 5 years after last subject has been enrolled. |
El final global de este estudio se definirá como el punto en el que todos los sujetos inscritos hayan completado todo el seguimiento especificado en el estudio (último sujeto, última visita en el último país donde se realizó el estudio) o el último sujeto muera o se retire del estudio en el último país en el que se realizó el estudio. Sin embargo, la duración máxima del ensayo es de 5 años después de la inscripción del último sujeto. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 8 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 8 |